Revolutionary, CLIA-Waived, Point-of-Care Testing. That’s the binx io.

Easy-to-use, molecular platform enabling single-visit diagnoses and treatment for chlamydia and gonorrhea.

Welcome to the future of sexually transmitted infection (STI) testing

The binx io offers a new paradigm designed to enable improved health outcomes by: • Increasing treatment compliance • Limiting onward transmission • Minimizing the risk of untreated conditions • Ensuring the right treatment is provided

Lab-quality test results in about 30 minutes

The world’s first first and only FDA-cleared, rapid, molecular point of care test for CT/NG

How the binx io Works

binx io is a CLIA-Waived desktop instrument that processes a single-use, assay-specific cartridge with no sample preparation necessary. binx io is fully automated, easy-to-use, and does not require calibration or preventative maintenance. Simply load the cartridge and in about 30-minutes the io provides a result that does not require any interpretation.

With billable testing administered under one roof, the io platform can generate valuable revenue for clinics. The binx io platform combines ultra-rapid, polymerase chain reaction (PCR) amplification with binx health’s proprietary and highly-sensitive electrochemical detection technology. This combination enables the io to provide results equivalent to the central laboratory in about 30 minutes.

io®, the io Instrument®, and the io Cartridge® (together the “io Diagnostic System®”) are registered trademarks of binx health limited. Copyright © 2020 binx health, inc. The binx health io CT/NG Assay, when tested using the binx health io Instrument, is a fully automated, rapid, qualitative test intended for use in point-of-care or clinical laboratory settings for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA by polymerase chain reaction. The binx health io CT/NG Assay is intended for use with female vaginal swab specimens, collected either by a clinician or self-collected by a patient in a clinical setting, or male urine specimens, as an aid in the diagnosis of symptomatic or asymptomatic Chlamydia trachomatis and/or Neisseria gonorrhoeae infection. For a symptomatic male patient with a chlamydia negative test result, further testing with a laboratory-based molecular test is recommended.

¹ The U.S. Centers for Disease Control and Prevention (2018). 2018 SEXUALLY TRANSMITTED DISEASES SURVEILLANCE REPORT. Updated August 27, 2019. https://www.cdc.gov/std/stats18/default.htm.

²,³ Huang W, Gaydos CA et al (2012). Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. STI. 88. Published first online 14 Sept 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671871/

Recent News


Published Literature


The binx health io CT/NG Assay has been cleared by the United States Food and Drug Administration for use with female vaginal swab specimens, collected either by a clinician or self-collected by a patient in a clinical setting, or male urine specimens.

In April 2019, the binx health io CT/NG Assay received CE-marking for both female vaginal swab and male urine samples.